Dr. Kipps is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
3855 Health Sciences Dr
La Jolla, CA 92093Phone+1 858-822-6100Fax+1 858-246-1847- Is this information wrong?
Education & Training
Stanford Health Care-Sponsored Stanford UniversityFellowship, Hematology, 1982 - 1984- Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 1979 - 1981
Harvard Medical SchoolClass of 1979
Certifications & Licensure
CA State Medical License 1980 - 2024- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2010-2014
- Top Doctors:San Diego Area Castle Connolly, 2013
- America's Top Doctors for Cancer Castle Connolly, 2009-2013
- Join now to see all
Clinical Trials
- Phase 2 Safety and Efficacy Study of AT-101 in Combination With Rituximab in Patients With Chronic Lymphocytic Leukemia Start of enrollment: 2006 Jan 01
- A Study to Evaluate the Treatment of Previously Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) Start of enrollment: 2006 Mar 01
- Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL) Start of enrollment: 2008 Feb 01
- Join now to see all
Publications & Presentations
PubMed
- Correction: a phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic HER2-negative breast cancer.Rebecca A Shatsky, Hemali Batra-Sharma, Teresa Helsten, Richard B Schwab, Emily I Pittman, Minya Pu, Elizabeth Weihe, Emanuela M Ghia, Laura Z Rassenti, Alfredo Molino...> ;Breast Cancer Research. 2024 Mar 13
- 1 citationsA phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic Her2-negative breast cancer.Rebecca A Shatsky, Hemali Batra-Sharma, Teresa Helsten, Richard B Schwab, Emily I Pittman, Minya Pu, Elizabeth Weihe, Emanuela M Ghia, Laura Z Rassenti, Alfredo Molino...> ;Breast Cancer Research. 2024 Feb 26
- A + AVD for Treatment of Hodgkin Lymphoma Variant of Richter's Transformation.Benjamin Heyman, Michael Choi, Thomas J Kipps> ;Case Reports in Hematology. 2024 Jan 1
- Join now to see all
Journal Articles
- SET Alpha and SET Beta mRNA Isoforms in Chronic Lymphocytic LeukaemiaDanielle M Brander, J Brice Weinberg, Daphne R Friedman, Thomas J Kipps, British Journal of Haematology
- Sustained Efficacy and Detailed Clinical Follow-up of First-Line Ibrutinib Treatment in Older Patients with Chronic Lymphocytic Leukemia: Extended Phase 3 Results from...Steven Coutre, Thomas J Kipps, Jan A Burger, Nancy L Bartlett, Paul M Barr, Haematologica
- MiR-125a and MiR-34a Expression Predicts Richter Syndrome in Chronic Lymphocytic Leukemia PatientsThomas J Kipps, John A Thorson, Blood
Abstracts/Posters
- High-Level ROR1 and BCL2, Cancer-Stemness, and BCL2 Mutations Associate with Venetoclax Resistance in Chronic Lymphocytic LeukemiaThomas J. Kipps, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Cirmtuzumab, a ROR1 Targeted Mab, Reverses Cancer Stemness, and Its Combination with Ibrutinib Is Safe and Effective: Planned Analysis of the Cirll Phase 1/2 Trial for...Thomas J. Kipps, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Durability of Responses on Continuous Therapy and Following Drug Cessation with Venetoclax and Rituximab: Long-Term Follow-up Analysis of a Phase 1b Study in Patients ...Thomas J. Kipps, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Lectures
- Approaches to Personalized Treatment for CLL: Expert Guidance on Sequencing Therapy and Novel Agents61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Ibrutinib Reduces Obinutuzumab-Gazyva Infusion Related Reactions (IRR) in Patients with Chronic Lymphocytic Leukemia (CLL) and It Is Associated with Changes on Plasma ...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Wnt5a Induces Association of ROR1 with Ca2+/Calmodulin-Dependent Protein Kinase II and ROR1-Dependent Calcium Influx in Chronic Lymphocytic Leukemia2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Press Mentions
Scientists Map Genetic Evolution of Chronic Lymphocytic Leukemia to Richter’s SyndromeDecember 11th, 2022- What's on Tap at the Society of Hematologic Oncology's 10th Annual MeetingSeptember 26th, 2022
- Oncternal Therapeutics : Lee 2022 ASCO Poster Zilovertamab + Ibrutinib for MCL and CLLJune 7th, 2022
- Join now to see all
Grant Support
- Specialized Cancer Center Support GrantNational Cancer Institute2011
- Chronic Lymphocytic Leukemia Research ConsortiumNational Cancer Institute2000–2011
- Antibody V Gene Expression B Cell Lymphocytic LeukemiaNational Cancer Institute1999–2011
- Lenalidomide Treatment And The Chronic Lymphocytic Leukemia MicroenvironmentNational Cancer Institute2009–2010
- Active Immune Therapy OT Leukemia Associated Antigens And Gene TherapyNational Cancer Institute2006–2010
- Tumor Therapy/Annihilation Using A Smart Nanoplatform (SNAP)National Cancer Institute2005–2009
- A CRC Phase 1 Study Of Clofarabine For Treatment Of Relapsed/Refractory CLLNational Center For Research Resources2006
- Administrative CoreNational Cancer Institute2006
- Phase I/II Study Of Xcellerated T Cells In Chronic Lymphocytic LeukemiaNational Center For Research Resources2005–2006
- Immune Monitoring In B Cell CLL Patients Treated With Ad-Cd154 CellsNational Center For Research Resources2005
- Gx15-070ms Every 3 Weeks For Refractory Chronic Lymphocytic LeukemiaNational Center For Research Resources2005
- Phase I/II Study Of Xcellerated T Cells In CLLNational Center For Research Resources2004
- Immune Monitoring In B Cell CLL Treated With Ad-Cd154National Center For Research Resources2004
- Competing Supplement For CLL Research ConsortiumNational Cancer Institute2003
- Translational OncologyNational Cancer Institute2001–2002
- Gene Transfer Of CD154 Into Myeloma Plasma CellsNational Center For Research Resources2000–2002
- Autoimmune Hemolytic Anemia And Expression Of IG GenesNational Center For Research Resources2000–2002
- Immunology Of CLL I--Acitive ImmunotherapyNational Cancer Institute2000–2002
- Phase I Study Of CD40 Ligand Transduced Leukemia Cells In CLLNational Center For Research Resources1999–2002
- Synovium As An Immune Underprivileged SiteNational Institute Of Arthritis And Musculoskeletal And Skin Diseases1998–2002
- Erb 2neu DNA Vaccines For Breast Cancer ImmunotherapyNational Cancer Institute1998–2002
- Core--Flow Cytometry FacilityNational Cancer Institute1994–2002
- Translational Oncology--Pathogenesis, Prognosis And Genetic SusceptibilityNational Cancer Institute2000
- Immunology Of CLL I--Active Immunotherapy &Autologous Stem Cell TransplantationNational Cancer Institute1999
- Chronic Lymphocytic Leukemia Research ConsortiumNational Cancer Institute1999
- Regulation Of CD40L On Lymphocytes In Systemic Lupus ErythematosusNational Center For Research Resources1998–1999
- Antibody V Gene Expression In B Cell CLLNational Cancer Institute1994–1998
- Immunoglobulin And Gene ExpressionNational Center For Research Resources1996–1997
- Effect Of N-Acetylcysteine On Lymphocyte Activation In Rheumatoid ArthritisNational Center For Research Resources1996–1997
- ERBB 2/Neu DNA Vaccines For Breast Cancer ImmunotherapyNational Cancer Institute1996–1997
- Erbb-2/Neu DNA Vaccines For Breast Cancer ImmunotherapyNational Cancer Institute1995–1997
- Immunobiology Of AIDS LymphomasNational Cancer Institute1994–1997
- Immunologic Aging And AutoimmunityNational Institute On Aging1992–1994
- Mechanisms Of Aids-Associated LymphomagenesisNational Cancer Institute1991–1994
- New Modalities For Active Immunotherapy Of MalignanciesNational Cancer Institute1992–1993
- Novel Therapeutic Approaches In Hiv-Associated LymphomasNational Cancer Institute1991–1993
- Antibody V Gene Expression In Human B Cell MalignanciesNational Cancer Institute1990–1993
- Immunologic Aging And AutoimmunityNational Institute On Aging1991
- Human Antibody Diversity In Health &AutoimmunityNational Institute Of Arthritis And Musculoskeletal And Skin Diseases1990
- Antibody V Gene Expression In Human B Cell MalignanciesNational Cancer Institute1989–1990
- Isolation And Function Of Switch Variant Monoclonal AntibodiesNational Institute Of Arthritis And Musculoskeletal And Skin Diseases1989
- Bone Marrow In Immunologic Aging And AutoimmunityNational Institute On Aging1987–1989
- Human Antibody Diversity In Health &AutoimmunityNational Institute Of Arthritis And Musculoskeletal And Skin Diseases1986–1989
- Multiparameter Fluorescence Activated Cell SorterNational Center For Research Resources1988
Other Languages
- German
Hospital Affiliations
UC San Diego Medical Center - HillcrestSan Diego, California
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
